• My Dashboard My Education Find an Ophthalmologist
  • Home
  • Coronavirus
  • For Ophthalmologists
    • Meetings
      • AAO 2022
        • Meeting Information
          • Past and Future Meetings
          • Mobile Meeting Guide
          • Contact Information
          • Annual Meeting News
          • Health and Safety
          • Policies and Disclaimers
        • Program
          • Program Highlights
          • Subspecialty Day
          • Virtual Meeting
          • Program Committees
          • CME
          • Meeting Archives
        • Expo
        • Registration
        • Hotels & Travel
          • Hotel Reservation Information
          • Chicago
          • International Attendees
          • Hotel Meeting Space
        • Presenter Central
          • Presenter Central
          • Abstract Selection Process
          • Submission Policies
          • Subject Classification/Topics
          • Instruction Courses and Skills Transfer Labs
          • Papers and Posters
          • Videos
          • Grand Rounds Symposium
          • Program Participant and Faculty Guidelines
          • Faculty Development Program
        • Exhibitors
          • Exhibitor Central
          • Exhibitor Portal Information
          • Exhibitor Prospectus
          • New Exhibiting Companies
          • Exhibitor Resources
          • International Exhibitors
          • Promotional Opportunities
          • Exhibitor Hotel Reservations
      • Mid-Year Forum
        • Registration and Travel
        • Congressional Advocacy Day
        • Advocacy Ambassador Program
        • Program
        • Schedule
        • Sponsored Attendees
        • News
      • Codequest
        • Codequest Instructors
        • Claim Codequest CME or CEU Credit
      • Eyecelerator
    • Clinical Education
      • COVID-19
      • Education
        • Browse All Education
        • Courses
        • Cases
        • Learning Plans
        • Interactive
        • Focal Points
        • Wills Eye Manual
        • Disease Reviews
        • Clinical Webinars
        • Diagnose This
        • Self-Assessments
        • Educational Centers
          • Glaucoma Education Center
          • Pediatric Ophthalmology Education Center
          • Laser Surgery Education Center
          • Myopia Resources
          • Oculofacial Plastic Surgery Center
          • Redmond Ethics Center
      • Journals
      • Guidelines
        • Browse All Practice Guidelines
        • Preferred Practice Patterns
        • Clinical Statements
        • Compendium Guidelines
        • Complementary Therapy Assessments
        • Medical Information Technology
        • Ophthalmic Technology Assessments
        • Patient Safety Statements
        • Choosing Wisely
        • Low Vision
        • Eye Care for Older Adults
        • Eye Disease Statistics
        • About the Hoskins Center
      • Video and Image Library
        • Browse All Videos
        • Clinical and Surgical Videos
        • Presentations and Lectures
        • 1-Minute Videos
        • Master Class Videos
        • Basic Skills Videos
        • Interviews
        • Images
        • Submit an Image
        • Submit a Video
      • Podcasts
        • Browse All Audio and Podcasts
        • Experts InSight
        • Ophthalmology Journal
      • News
        • Browse All Clinical News
        • Editors' Choice
        • Headlines
        • Current Insight
      • CME Central
        • Browse All CME Activities
        • Claim CME Credit and View Transcript
        • CME Planning Resources
        • Complete Your Financial Disclosure
        • Joint Sponsorship Portal
        • LEO Continuing Education Recognition Award
        • Safe ER/LA Opioid Prescribing
        • Check Your Industry Payment Records
      • MOC
      • Resident Education
        • Resident Education Home
        • Browse All Resident Content
          • Courses
          • Flashcards
          • Interactive Cases and Simulations
          • Videos
          • Webinars
        • OKAP and Board Exam Resources
          • OKAP Exam
          • Board Prep Resources
          • OKAP and Board Review Presentations
          • Study Flashcards
        • Cataract Master
        • Diversity and Inclusion Education
        • News and Advice from YO Info
        • Pediatric Ophthalmology Education Center
        • PGY-1 and PGY-2 Resources
        • Simulation in Resident Education
    • Membership
      • Join
      • Renew
      • Current Member
      • Volunteer
      • Physician Wellness
      • Member Directory
      • Member Obituaries
      • AAOE Membership
    • Advocacy
      • Advocacy News
      • Get Involved
        • Ways to Give
        • How to Get Involved
        • Congressional Advocacy
        • Support the Academy's Agenda
        • Research Legislation
        • Find Your Legislators
        • I Am an Advocate
        • Advocacy at Home
        • Advocate Tools
        • Best Practices for Advocating at Home
        • Social Media Toolkit
        • Letter to Editor
        • Town Hall Guide
        • Guide to Engaging With New Lawmakers
        • Resources
        • Attending a Political Fundraiser
      • OPHTHPAC
        • About Us
        • Join OPHTHPAC
        • OPHTHPAC Blog
      • Surgical Scope Fund
        • Support Surgery By Surgeons
        • Surgery By Surgeons Blog
    • Publications
      • EyeNet Magazine
        • Latest Issue
        • Archive
        • Subscribe
        • Advertise
        • Write For Us
        • Corporate Lunches
        • Contact
        • MIPS 2022
      • Focal Points
      • Ophthalmology
      • Ophthalmology Glaucoma
      • Ophthalmology Retina
      • YO Info
      • Scope
    • Subspecialties
      • Cataract/Anterior Segment
      • Comprehensive Ophthalmology
      • Cornea/External Disease
      • Glaucoma
      • Neuro-Ophthalmology/Orbit
      • Ocular Pathology/Oncology
      • Oculoplastics/Orbit
      • Pediatric Ophthalmology/Strabismus
      • Refractive Management/Intervention
      • Retina/Vitreous
      • Uveitis
    • IRIS Registry
      • About
      • Using the Registry
        • User Guide
        • Medicare Reporting
        • Maintenance of Certification
        • Non-EHR Reporting
      • Sign Up
        • Application Process
        • Why Participate
        • Once You've Applied: Getting Started
        • What Practices Are Saying About the Registry
      • Requirements
        • EHR Systems
        • Data & Technical Needs
      • Research
      • Registry Dashboard
      • News
      • Medicare & MIPS
    • Medicare Information
    • Diversity, Equity, and Inclusion
  • For Practice Management
    • Managing Your Practice
      • Managing Your Practice Topics
      • Coronavirus Resources
      • Reopening & Recovery
      • Practice Forms Library
      • Practice Management News and Advice
      • AAOE-Talk
      • Video Library
      • Ophthalmology Job Center
      • Benchmarking and Salary Tools
      • Academy Consultations
      • Consultant Directory
    • Coding
      • Coding Topics
      • Codequest Events
      • Ask the Coding Experts
      • Coding Updates and Resources
      • Coding for Injectable Drugs
      • EM Documentation
      • ICD-10-CM
      • Ophthalmic Coding Specialist (OCS) Exam
      • Retina
      • Savvy Coder
    • Webinars and Events
      • Annual Meeting
      • Codequest Courses
      • Mid-Year Forum
      • Webinar Recordings
    • IRIS Registry
      • Merit-Based Incentive Payment
    • Medicare and MIPS
      • MIPS
        • Quality
        • Promoting Interoperability
        • Improvement Activities
        • Cost
        • Avoid a Penalty
      • Resources
      • Medicare Participation Options
      • Medicare Advantage Plans
      • New Medicare Card
      • Provider Enrollment, Chain and Ownership System (PECOS)
    • Regulatory Compliance
      • HIPPA Resources
      • Office of Inspector General
      • Audits
      • OSHA
    • AAOE Membership
      • Join AAOE
      • Membership Benefits
      • Renew/Pay Dues
    • About AAOE
      • AAOE Board of Directors
      • AAOE Content Committee
      • Volunteer Opportunities
  • For Public & Patients
    • Eye Health A-Z
    • Symptoms
    • Glasses & Contacts
    • Tips & Prevention
    • News
    • Ask an Ophthalmologist
    • Patient Stories
    • No Cost Eye Exams
    • Español
      • A - Z de Salud Ocular
      • Síntomas
      • Anteojos y Lentes de Contacto
      • Consejos y Prevención
      • Noticias
      • Relatos de Pacientes
      • Exámenes de la vista sin costo
      • English
  • AAO 2022
    • Meeting Information
      • Past and Future Meetings
      • Mobile Meeting Guide
      • Contact Information
      • Annual Meeting News
      • Health and Safety
      • Policies and Disclaimers
    • Program
      • Program Highlights
      • Subspecialty Day
      • Virtual Meeting
      • Program Committees
      • CME
      • Meeting Archives
    • Expo
    • Registration
    • Hotels & Travel
      • Hotel Reservation Information
      • Chicago
      • International Attendees
      • Hotel Meeting Space
    • Presenter Central
      • Presenter Central
      • Abstract Selection Process
      • Submission Policies
      • Subject Classification/Topics
      • Instruction Courses and Skills Transfer Labs
      • Papers and Posters
      • Videos
      • Grand Rounds Symposium
      • Program Participant and Faculty Guidelines
      • Faculty Development Program
    • Exhibitors
      • Exhibitor Central
      • Exhibitor Portal Information
      • Exhibitor Prospectus
      • New Exhibiting Companies
      • Exhibitor Resources
      • International Exhibitors
      • Promotional Opportunities
      • Exhibitor Hotel Reservations
  • About
    • Who We Are
      • What We Do
      • About Ophthalmology
      • The Eye Care Team
      • Ethics and the Academy
      • History
      • Museum of Vision
      • Values
    • Governance
      • Council
      • Board of Trustees
      • Committees
      • Academy Past Presidents
      • Secretariats
      • Elections
      • Academy Blog
      • Academy Staff Leadership
    • Leadership Development
    • Awards
      • Laureate Recognition Award
      • Outstanding Advocate Award
      • Outstanding Humanitarian Service Award
      • International Blindness Prevention Award
      • Distinguished Service Award
      • Guests of Honor
      • Secretariat Award
      • Straatsma Award
      • Achievement Award Program
      • Artemis Award
      • EnergEYES Award
      • International Education Award
      • International Scholar Award
      • Commitment to Advocacy Award
      • Visionary Society Award
    • Financial Relationships
    • Policy Statements
    • Related Organizations
      • Subspecialty/Specialized Interest Society Directory
      • State Society Directory
      • Subspecialty/Specialized Interest Society Meetings
      • State Society Meetings
      • Resources for Societies
    • Year in Review
      • 2020 Year in Review
  • Foundation
    • About
      • 2020-2021 Annual Report
      • Annual Report Archives
      • News From the Chair
      • Foundation Staff
    • Our Impact
      • Partners for Sight
      • Donor Spotlights
      • Global Ophthalmic Community
      • Sponsorships
      • Patients and the Public
    • Giving Options
      • Our Supporters
      • Estate and Planned Giving
      • Ophthalmic Business Council
      • Parke Center Campaign
      • Minority Ophthalmology Mentoring Campaign
      • Museum of the Eye Campaign
    • Orbital Gala
      • Why Attend
      • Photo Recap
      • Corporate Support Opportunities
      • Tribute Gifts
      • Silent Auction
      • Corporate Sponsors
    • Donate
    • Museum of the Eye Campaign
      • Museum Supporters
  • Museum of the Eye
    • Visit
    • What's On
      • Museum Galleries
      • Special Exhibitions
      • Current Events
      • Past Events
    • Explore
      • Research and Resources
      • Collection Search
      • Previous Exhibits
      • Oral Histories
      • Biographies
    • Volunteer
    • Mailing List
    • Donate
    • About the Museum
      • Museum Blog
  • Young Ophthalmologists
    • YO Info
    • Learn to Bill
    • Engage with the Academy
  • Senior Ophthalmologists
    • Scope
    • Practice Transitions
  • International Ophthalmologists
    • Global Programs and Resources for National Societies
    • Awards
    • Global Outreach
  • Residents
  • Medical Students
×
Shop
Log In Create an Account
  • For Ophthalmologists
  • For Practice Management
  • For Public & Patients
  • Coronavirus
  • About
  • Foundation
  • Museum of the Eye
  • COVID-19
  • Journals
  • Education
    • Education
    • Courses
    • Cases
    • Learning Plans
    • Interactive
    • Focal Points
    • Wills Eye Manual
    • Disease Reviews
    • Clinical Webinars
    • Diagnose This
    • Self-Assessments
    • Education Centers
      • Glaucoma Education Center
      • Pediatric Ophthalmology Education Center
      • Laser Surgery Education Center
      • Oculofacial Plastic Surgery Center
      • Redmond Ethics Center
      • Myopia Resources
      • Thyroid Eye Disease Resources
  • Guidelines
    • Practice Guidelines
    • Preferred Practice Patterns
    • Clinical Statements
    • Ophthalmic Technology Assessments
    • Patient Safety Statements
    • Complementary Therapy Assessments
    • Compendium Guidelines
    • Medical Information Technology
    • Low Vision
    • Choosing Wisely
    • Eye Care for Older Adults
    • Eye Disease Statistics
    • About the Hoskins Center
    • Artificial Intelligence
    • Premium IOLs
    • Patient-Reported Outcomes with LASIK Symptoms and Satisfaction
  • Multimedia
    • Multimedia Library
    • Video
      • 1-Minute Videos
      • Presentations and Lectures
      • Master Class Videos
      • Basic Skills Videos
      • Clinical and Surgical Videos
      • Interviews
      • Resident Lectures
      • Submit a Video
      • YO Video Contest
    • Podcasts
      • Browse Podcast Archive
      • Experts InSight Podcast
      • Ophthalmology Journal Podcast
    • Images
      • Submit an Image
  • News
    • Clinical News
    • Editors' Choice
    • Headlines
    • Current Insight
  • CME
    • CME Central
    • Claim CME Credit and View Transcript
    • CME Planning Resources
    • Complete Your Financial Disclosure
    • Joint Sponsorship Portal
    • LEO Continuing Education Recognition Award
    • Safe ER/LA Opioid Prescribing
    • Check Your Industry Payment Records
  • MOC
  • Residents
    • Resident Education Home
    • Browse All Resident Content
      • Courses
      • Flashcards and Study Presentations
      • Interactive Cases and Simulations
      • Videos
      • Webinars
    • Cataract Master
    • Diversity and Inclusion Education
    • News and Advice from YO Info
    • OKAP and Board Exam Resources
      • OKAP Exam
      • Board Prep Resources
      • OKAP and Board Review Presentations
      • Study Flashcards
    • Pediatric Ophthalmology Education Center
    • PGY-1 and PGY-2 Resources
    • Resident Knowledge Exchange
    • Simulation in Resident Education
    • Clinical Education /
    • Book Excerpts /
    • Basic and Clinical Science Course - Excerpt
  • 2020–2021 BCSC Basic and Clinical Science Course™

    Go to Academy Store Learn more and Purchase.

    7 Oculofacial Plastic and Orbital Surgery

    Part I: Orbit

    Chapter 4: Orbital Inflammatory and Infectious Disorders

    Noninfectious Inflammation

    Thyroid Eye Disease

    Thyroid eye disease (TED; also known as Graves ophthalmopathy, thyroid-associated orbitopathy, and other terms) represents an autoimmune inflammatory disorder with characteristic clinical signs (Figs 4-7, 4-8, 4-9, 4-10). Originally described as part of the triad of Graves disease (orbital signs, hyperthyroidism, and pretibial myxedema), TED most often occurs in individuals with Graves hyperthyroidism. However, TED may also occur with Hashimoto thyroiditis (immune-induced hypothyroidism) or in the absence of thyroid dysfunction. The course of the eye disease does not necessarily parallel the activity of the thyroid gland or the treatment of thyroid abnormalities.

    Figure 4-7 Active thyroid eye disease (TED) in a patient demonstrating bilateral chemosis, conjunctival injection, and caruncular edema.

    (Courtesy of Bobby S. Korn, MD, PhD.)

    Figure 4-8 Restrictive strabismus causing marked esotropia in a patient with relative enlargement of the right medial rectus muscle.

    (Courtesy of Bobby S. Korn, MD, PhD.)

    Figure 4-9 A patient with TED demonstrates bilateral upper and lower eyelid retraction, proptosis, and lateral flare.

    (Courtesy of Bobby S. Korn, MD, PhD.)

    Figure 4-10 A patient with asymmetric TED. A, Right upper eyelid retraction. B, Left relative exophthalmos. C, Right upper lid lag with downgaze. D, Bilateral lagophthalmos with inferior corneal exposure on the right.

    (Courtesy of Bobby S. Korn, MD, PhD.)

    See Key Points 4-1.

    KEY POINTS 4-1

    Thyroid eye disease (TED) The following list highlights the essential points for the ophthalmologist to remember about TED.

    • Eyelid retraction is the most common clinical feature of TED (and TED is the most common cause of eyelid retraction).

    • TED is the most common cause of unilateral or bilateral proptosis.

    • TED may be markedly asymmetric.

    • TED is associated with hyperthyroidism in 90% of patients, but 6% of patients may be euthyroid.

    • Severity of TED usually does not parallel serum levels of triiodothyronine (T3) or free thyroxine (T4).

    • TED is up to 6 times as common in women as in men.

    • Smoking is associated with increased risk and severity of TED.

    • Urgent care may be required for optic neuropathy or severe proptosis with corneal decompensation.

    • If surgery is needed, the usual order is orbital decompression, followed by strabismus surgery, followed by eyelid retraction repair (see Chapter 7 in this volume).

    • Radiotherapy may prevent optic neuropathy and may improve some aspects of TED, but its role remains controversial.

    Diagnosis

    The diagnosis of TED is made when 2 of the following 3 signs are present:

    1. Concurrent or recently treated immune-related thyroid dysfunction:

      1. Graves hyperthyroidism

      2. Hashimoto thyroiditis

      3. Presence of circulating thyroid antibodies without a coexisting dysthyroid state (partial consideration given): thyroid-stimulating hormone–receptor (TSH-R) antibodies, thyroid-binding inhibitory immunoglobulins, thyroid-stimulating immunoglobulins, antimicrosomal antibodies

    2. Typical ocular signs:

      1. Chemosis and/or caruncular edema (see Fig 4-7)

      2. Restrictive strabismus in a typical pattern (see Fig 4-8)

      3. Unilateral or bilateral eyelid retraction with typical lateral flare (see Fig 4-9)

      4. Unilateral or bilateral proptosis (in comparison with old photos of the patient)

      5. Compressive optic neuropathy

      6. Fluctuating eyelid edema and/or erythema

    3. Radiographic evidence of TED: unilateral or bilateral fusiform enlargement any of the rectus muscles and/or the levator muscle complex (Figs 4-11, 4-12).

    Figure 4-11 TED. Axial orbital CT scan shows characteristic fusiform extraocular muscle enlargement (yellow arrow) that spares the tendons (red arrow).

    (Courtesy of Julian D. Perry, MD.)

    Figure 4-12 Coronal orbital CT scan shows bilateral enlargement of extraocular muscles in TED.

    (Courtesy of Keith D. Carter, MD.)

    Serologic testing, using serum thyroid-stimulating hormone (TSH), triiodothyronine (T3), and free thyroxine (T4) levels, is well established in the diagnosis of thyroid disease. However, the usefulness of these tests in monitoring TED treatment and progression is unclear, because the systemic disease and the eye disease are discordant.

    Tests of autoimmune function may be helpful in evaluating disease activity and severity. TSH-R antibody testing can be performed by measuring all immunoglobulins targeting the TSH-R (eg, the thyrotropin-binding inhibitory immunoglobulin [TBII] test) or by measuring only the stimulating antibodies (eg, the thyroid-stimulating immunoglobulin [TSI] assay).

    These tests may help identify the cause of the thyroid disease and may help identify patients at high risk for TED; however, results should be interpreted with caution because the diagnosis of TED is based mainly on clinical findings. Thyroid peroxidase antibody testing has replaced antimicrosomal antibody testing; however, the presence of this antibody does not correlate with TED activity or severity or TSI levels. Similarly, thyroglobulin antibody levels do not correlate with TED. Insulin-like growth factor I (IGF-I) antibody levels may represent a future area of serologic testing for TED; however, no current recommendations exist.

    Patients presenting with only orbital signs require observation for other orbital diseases or the development of a dysthyroid state.

    • Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9–14.

    • Srinivasan A, Kleinberg TT, Murchison AP, Bilyk JR. Laboratory investigations for diagnosis of autoimmune and inflammatory periocular disease: Part II. Ophthalmic Plast Reconstr Surg. 2017;33(1):1–8.

    Pathogenesis

    Orbital fibroblasts, through the expression of characteristic surface receptors, gangliosides, and proinflammatory genes, play an active role in modulating the inflammatory process. Unlike fibroblasts from other body sites, orbital fibroblasts express CD40 receptors, which are generally found on B cells. When engaged by T-cell–bound CD154, several fibroblast proinflammatory cytokines are upregulated, including interleukin-6 (IL-6) and interleukin-8 (IL-8), as well as prostaglandin E2, increasing synthesis of hyaluronan and glycosaminoglycan (GAG). This upregulation of orbital fibroblast GAG synthesis represents an essential aspect of the pathology of TED, and it occurs at a rate 100 times that of abdominal fibroblasts from the same patient. Therapeutic levels of corticosteroids dampen the upregulation cascade.

    Orbital fibroblasts, which are embryologically derived from the neural crest lineage, possess developmental plasticity. A subpopulation of orbital fibroblasts appears capable of undergoing adipocyte differentiation, contributing to the expansion of orbital fat that predominates in some patients.

    A circulating immunoglobulin that recognizes and activates the insulin-like growth factor I receptor (IGF-IR) expressed on the surface of orbital fibroblasts of individuals with Graves disease may stimulate orbital fibroblasts to secrete GAGs, cytokines, and chemoattractants. These latter signaling families may contribute to orbital inflammation and congestion.

    • Kazim M, Goldberg RA, Smith TJ. Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol. 2002;120(3):380–386.

    • Naik V, Khadavi N, Naik MN, et al. Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy. Thyroid. 2008;18(9):967–971.

    • Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181(6):4397–4405.

    Epidemiology

    A 1996 epidemiologic study of white patients with TED in the United States determined that the overall age-adjusted incidence per 100,000 population per year was 16 cases for women compared with 3 cases for men. The peak incidences occurred in the age groups 40–44 years and 60–64 years in women and 45–49 years and 65–69 years in men. Development of TED is up to 7 times as likely for smokers when compared to nonsmokers.

    Clinical features

    Among patients with TED, about 90% have Graves hyperthyroidism, 6% are euthyroid, 3% have Hashimoto thyroiditis, and 1% have primary hypothyroidism. A close temporal relationship exists between the development of hyperthyroidism and the development of TED: in about 20% of patients, the diagnoses are made at the same time, and in about 60% of patients, the eye disease occurs within 1 year of onset of the thyroid disease. For patients who have no history of abnormal thyroid function or regulation at the time TED is diagnosed, the risk for development of thyroid disease is about 25% within 1 year and 50% within 5 years. Although hyperthyroidism is present or will develop in most patients with TED, only about 30% of patients with autoimmune hyperthyroidism will develop TED.

    Pretibial myxedema accompanies TED in about 4% of patients. Acropachy (soft-tissue swelling and periosteal changes affecting the distal extremities, principally fingers and toes) accompanies TED in about 1% of patients. Both are associated with a poor prognosis for the orbitopathy. Myasthenia gravis occurs in fewer than 1% of patients and should be considered when ptosis accompanies TED.

    The most frequent presenting ocular symptoms and signs of TED are a dull, deep orbital pain or discomfort (30% of patients), lid lag with downgaze (unilateral or bilateral, 50%; see Fig 4-10), and upper eyelid retraction (unilateral or bilateral, 75%). Symptomatic dysthyroid optic neuropathy is present in less than 2% of eyes at the time of diagnosis of TED.

    Upper eyelid retraction occurs in more than 90% of patients during their clinical course (see Fig 4-9); exophthalmos (unilateral or bilateral) in 60%; restrictive extraocular myopathy in 40%; and optic neuropathy (unilateral or bilateral) in 5%. Only 5% of patients develop the complete constellation of these 4 classic findings and hyperthyroidism. Some degree of diplopia is reported by about 17% of patients, lacrimation or photophobia by 15%–20% of patients, and blurred vision by 7% of patients.

    • Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–290.

    Treatment and prognosis

    TED is a self-limiting disease that on average lasts 1 year in nonsmokers and between 2 and 3 years in smokers. After the active disease plateaus, a quiescent “burnt-out” phase that follows Rundle’s curve ensues (Fig 4-13). Reactivation of inflammation occurs in 5%–10% of patients over their lifetime.

    Although several clinical scoring systems to guide TED evaluation and treatment exist, including NO SPECS, Clinical Activity Score (CAS), and VISA, no system prevails. The CAS and VISA systems each assign points for various findings; the CAS adds extra parameters for follow-up visits and the VISA uses the same scale for both initial and follow-up visits. Treatment of patients with TED follows a stepwise and graded approach based on symptoms, clinical examination, and ancillary testing (Tables 4-3, 4-4).

    Figure 4-13 Rundle’s curve as applied to the typical course of TED.

    Table 4-3 VISA and CAS Inflammatory Scoring Systems

    Most patients with TED in the active phase require only smoking cessation and supportive care, including use of topical ocular lubricants. The following may also be helpful:

    • topical cyclosporine, which may reduce ocular surface irritation

    • a reduced-salt diet and sleeping with the head of the bed elevated, which may limit orbital edema

    • wearing wraparound sunglasses, which may relieve exposure and dry eye symptoms

    • temporary prism glasses, which may help maintain binocular fusion

    In addition, selenium supplementation may improve the course of disease, especially in patients heralding from selenium-deficient regions. Neurotoxins can temporarily improve upper eyelid retraction by weakening the eyelid elevators. Neurotoxins can also be used to treat restrictive strabismus by weakening affected extraocular muscle(s).

    Severe orbital inflammation may mandate early intervention to improve corneal exposure, globe subluxation, or optic neuropathy. Therapies generally attempt to decrease orbital congestion and inflammation (eg, glucocorticoids, biologics, radiotherapy), mechanically protect the cornea (eg, tarsorrhaphy), expand the orbital bony volume (eg, bony orbital decompression), or reduce orbital soft tissue volume (eg, fatty orbital decompression).

    Table 4-4 Management of Thyroid Eye Disease

    Mild disease

    • Observation

    • Patient education and lifestyle changes

      • Smoking cessation

      • Salt restriction

      • Elevation of head of bed

      • Use of sunglasses

    • Ocular surface lubrication

    • Establishment of a euthyroid state

    • Oral selenium

    Moderate disease

    • Topical cyclosporine

    • Eyelid taping at night

    • Moisture goggles or chambers

    • Prism glasses or selective ocular patching

    • Moderate-dose oral corticosteroid therapy

    Severe disease

    • High-dose intravenous corticosteroid therapy

    • Surgical orbital decompression (followed by strabismus surgery and/or eyelid surgery)

    • Periocular radiotherapy

    Refractory disease

    • Steroid-sparing immunomodulators

    Establishing the euthyroid state represents a mainstay of therapy. Hyperthyroidism is most commonly treated with antithyroid drugs and sometimes with radioactive iodine (RAI). In some patients, RAI treatment may worsen TED, presumably because the TSH-R antigen release incites an enhanced immune response. In addition, hypothyroidism occurring after RAI treatment may exacerbate TED via stimulation of TSH-R. Exacerbation of TED after RAI treatment may occur more commonly in hyperthyroid patients with severe, active TED, those with elevated T3 levels, and smokers. Oral glucocorticoid treatment tapered over 3 months may limit TED progression in patients with risk factors such as these, but it is not indicated for patients without preexisting TED and without risk factors. Another strategy, termed block-and-replace therapy (eg, with iodine 131, methimazole, and thyroxine) reduces exacerbation of eye findings by limiting posttreatment TSH spikes. A third strategy, usually reserved for patients whose disease is refractory to RAI or those with severe TED, involves thyroidectomy, which creates hypothyroidism without extended antigen release.

    Patients with active TED featuring compressive optic neuropathy or other significant activity based on scoring systems (eg, VISA, CAS) may benefit from IV glucocorticoid treatment. Typical regimens vary from 500 mg to 1 g methylprednisolone weekly for 6–12 weeks, with a maximum dose of approximately 6 g in most cases and up to 8 g in severe cases. Hepatic function should be checked before administration and monitored throughout treatment due to potentially fatal hepatotoxicity. For oral glucocorticoids, which are now less commonly used than they were in the past, the usual starting dose is 1 mg/kg prednisone for 2–4 weeks until a clinical response is apparent. The dose is then reduced as rapidly as possible, based on the clinical response of optic nerve function. Although effective, high-dose glucocorticoids are associated with an extensive list of potential systemic adverse effects, limiting their long-term use. Refractory cases of optic neuropathy and vision-threatening exposure keratopathy may require additional treatments, such as orbital radiotherapy or decompressive surgery.

    Some reports suggest that treatment with fractionated orbital radiotherapy improves compressive optic neuropathy and other signs of TED in some patients, possibly by inducing terminal differentiation of fibroblasts and killing tissue-bound monocytes, which play an important role in antigen presentation. Recent evidence has suggested it may provide a protective effect against the development of optic neuropathy. Given the biologic effects of radiation, it is likely more useful in the active phase of the disease. Although radiation has been used for decades, a wealth of data exists to both support and refute its use, with and without the use of glucocorticoids, for many signs and symptoms of TED. Radiation therapy carries a rare risk of exacerbating diabetic retinopathy or other ischemic retinopathies.

    Treatment with rituximab may affect the clinical course of TED by blocking the CD20 receptor on B lymphocytes; however, it does not appear to target the central mechanisms of the disease, and most clinicians currently use this only as a second-line therapy in select cases. Tocilizumab, a monoclonal IL-6 antibody, may reduce inflammatory signs and even TSI via an upstream effect on the inflammatory cycle. A variety of other anti-inflammatory, antimetabolite, and biologic agents have been employed with limited success.

    In a recent clinical trial, teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, reduced exophthalmos and the CAS in patients with active ophthalmopathy. Teprotumumab may specifically target the autoimmune process underlying TED. This new therapeutic agent appears well tolerated; hyperglycemia in patients with diabetes mellitus represents the main adverse effect.

    In patients with active TED, orbital decompression treats optic neuropathy and severe exposure keratopathy that is refractory to medical therapy. In the postinflammatory phase of the condition, the first stage of surgical rehabilitation is decompression to address disfiguring or symptomatic proptosis. Preoperative CT imaging details the relative contributions of extraocular muscle enlargement and fat expansion to the proptosis (see Figs 4-11, 4-12). Patients with more enlargement of the orbital fat compartment (type I orbitopathy) may benefit from more fatty decompression, whereas patients with more extraocular muscle enlargement (type II orbitopathy) may benefit from more bony decompression. Fat and bone removal can be combined, graded, and tailored to achieve different amounts of proptosis reduction while minimizing adverse effects, such as diplopia, hypoglobus, and sinusitis. See Chapter 7 for further discussion of orbital decompression.

    Because decompression may produce or worsen diplopia, it should precede strabismus surgery, which may help restore single vision in patients with intractable diplopia in primary gaze or in the reading position. Prisms represent another option for patients with relatively comitant strabismus or for patients with a small deviation after strabismus surgery.

    Surgery to recess the rectus muscles can change eyelid position, so strabismus surgery typically precedes eyelid repositioning surgery. Levator and/or Müller muscle recession improves upper eyelid retraction to decrease corneal exposure and help improve appearance. The lower eyelids can be repositioned as well, typically by recessing the eyelid retractors, with or without a spacer graft or during a midface-lift. Finally, the last stage of surgery includes redraping of the eyelid skin and subcutaneous tissues. These techniques often address redundant skin and fatty tissues in addition to concomitant and independent periocular aging changes.

    Elective orbital decompression, strabismus surgery, and eyelid retraction repair are usually not considered until achieving a euthyroid state with stable ophthalmic signs for at least 6 to 9 months.

    Fortunately, treatment usually mitigates vision loss from optic neuropathy and prism glasses typically treat persistent diplopia. Subjectively, however, more than 50% of patients believe that their eyes look abnormal, and 38% of patients are dissatisfied with the appearance of their eyes. Thus, although significant long-term functional impairment from TED remains uncommon, the disease leaves lasting psychological and aesthetic sequelae.

    • Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338(2):73–78.

    • Chundury RV, Weber AC, Perry JD. Orbital radiation therapy in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2016;32(2):83–89.

    • Dolman PJ, Rootman J. VISA classification for Graves orbitopathy. Ophthalmic Plast Reconstr Surg. 2006;22(5):319–324.

    • Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–1761.

    Excerpted from BCSC 2020-2021 series: Section 10 - Glaucoma. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.

  • Most Commented
    Loading, please wait...
    There are no comments available.
    Most Viewed
    Loading, please wait...
    Most Viewed content is not available.
  • The Academy Store
    2022-2023 Basic and Clinical Science Course, Complete Print Set
    2022-2023 Basic and Clinical Science Course, Complete eBook Set
    2022-2023 Basic and Clinical Science Course, Complete Print and eBook Set
    2022-2023 Basic and Clinical Science Course, Residency Print Set
    2022-2023 Basic and Clinical Science Course, Residency eBook Set
    2022-2023 Basic and Clinical Science Course Complete Set
    2022-2023 Basic and Clinical Science Course Residency Set
    2022-2023 Basic and Clinical Science Course, Section 01: Update on General Medicine
    2022-2023 Basic and Clinical Science Course, Section 02: Fundamentals and Principles of Ophthalmology
    2022-2023 Basic and Clinical Science Course, Section 03: Clinical Optics and Vision Rehabilitation
    2022-2023 Basic and Clinical Science Course, Section 04: Ophthalmic Pathology and Intraocular Tumors
    2022-2023 Basic and Clinical Science Course, Section 05: Neuro-Ophthalmology
    2022-2023 Basic and Clinical Science Course, Section 06: Pediatric Ophthalmology and Strabismus
    2022-2023 Basic and Clinical Science Course, Section 07: Oculofacial Plastic and Orbital Surgery
    2022-2023 Basic and Clinical Science Course, Section 08: External Disease and Cornea
    2022-2023 Basic and Clinical Science Course, Section 09: Uveitis and Ocular Inflammation
    2022-2023 Basic and Clinical Science Course, Section 10: Glaucoma
    2022-2023 Basic and Clinical Science Course, Section 11: Lens and Cataract
    2022-2023 Basic and Clinical Science Course, Section 12: Retina and Vitreous
    2022-2023 Basic and Clinical Science Course, Section 13: Refractive Surgery
    The Technician Point System: How to Improve Practice Accountability and Bottom Line (Free Member Webinar)
    Transitioning Your Practice: Retiring, Selling or Buying a Practice (Free Member Webinar)
    2022 IRIS Registry (Intelligent Research in Sight) Preparation Kit
    Advances in Medical and Surgical Management: The 2022 Update on Glaucoma
    Presbyopia-Correcting IOLs
    2022 Codequest - Multistate (Recorded March 29)
    2022 Codequest Virtual (Multistate)
    Retina Patient Education Video Collection
    Cataract and Refractive Surgery Patient Education Video Collection
    Glaucoma Patient Education Video Collection
 
  • Contact Us
  • About the Academy
  • Jobs at the Academy
  • Financial Relationships with Industry
  • Medical Disclaimer
  • Privacy Policy
  • Terms of Service
  • Help
  • For Advertisers
  • For Media
  • Ophthalmology Job Center

OUR SITES

  • EyeWiki
  • International Society of Refractive Surgery

FOLLOW THE ACADEMY

Medical Professionals

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

Public & Patients

  • Facebook
  • Twitter
  • Instagram
  • YouTube

Museum of the Eye

  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • Trip Advisor
  • Yelp
© American Academy of Ophthalmology 2022